APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Clinical trial NCT04858334 · RECRUITING
Trial details
- NCT number
- NCT04858334
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-22
- Primary completion
- 2027-10-31
- Enrollment
- 152
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.